Arsenicals | Bioavailability | System | Major Findings | Reference |
---|---|---|---|---|
Orpiment | Low | In vitro | Dissolution increase with pH increase | Lantz et al., 1995; Floroiu et al., 2004 |
Low GI absorption | Hamster | 80% in feces; DMA in urine | Marafente and Vahter, 1987 | |
Reaglar | 4% | Human | MMA, DMA in urine | Koch et al., 2007 |
Low | Rat | Blood > lung, heart > spleen > liver, kidney | Wang et al., 2003 | |
Nanoparticles | Cell and rat | Increased bioavailability | Wu and Ho, 2006 | |
Arsenic trioxide | High | Rabbit | As3+ in blood, DMA in liver and lung | Lin et al., 2005 |
Human | 60% i.v. dose recovery in urine | Fujisawa et al., 2007 | ||
|
| Human | Oral equals to i.v. bioavailability |
Kumana et al., 2002
|